SEP 01, 2016 4:58 AM PDT

Drug Clears Toxic Protein Clusters in Alzheimer's Brain

WRITTEN BY: Xuan Pham
The beloved actor Gene Wilder died earlier this week from complications of Alzheimer’s disease. He was one of the tens of thousands of people who succumb to the disease, according to the Centers for Disease Control and Prevention.
 
But there’s some hope peeking through the grim statistics of this disease. Scientists recently announced highly promising results of a drug that purportedly can erase the toxic protein clumps in the Alzheimer brain.
 
Promising results for experimental Alzheimer drug | Image: pexels.com
The drug, known as aducanumab, targets the amyloid beta plaques in the brains of animal models, and now also in human clinical trials. As this drug progresses to Phase 3 to test efficacy in a larger group of patients, researchers are hopeful it will become the first drug to actually reverse Alzheimer pathology.
 
Amyloid plaque clumps (yellow) in the brainAlzheimer’s disease is pathologically defined with the presence of amyloid beta protein clumps in the brain. These are toxic to neurons and interfere with memory, cognition, and other normal functions of the brain. The CDC estimated 85,000 people died from Alzheimer’s disease in 2015; however, this number is believed to be an underestimate, as many deaths may not be correctly attributed to Alzheimer’s.
 
Aducanumab is an immune compound that appears to stimulate the body to remove the toxic amyloid clumps. In the latest study, scientists split 165 patients with mild Alzheimer’s disease into two groups: those who received aducanumab and those who received a placebo. This was done for 1 year, with the intent on demonstrating that the drug was safe to take.
 
Indeed, researchers found encouragement beyond safety. Through analyzing brain scans, the team found that patients treated aducanumab had less amyloid plaques than those treated with the placebo.
 
"After one year, you can see no red on the image, meaning the amyloid has almost completely
disappeared," said Dr. Roger Nitsch, a co-author of the study and the director of the Institute for Regenerative Medicine at the University of Zurich.
 
In addition, there was a direct correlation between dose and effect – the higher the dose, the greater the clearance of the toxic protein clumps. Notably, however, the higher dosages were also associated with more side effects.
 
Though the purpose of the study was to establish safety, the team did carry out some memory tests with some promising results. "We believe that's a hint of efficacy," study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen,
 
"We're encouraged that, there appeared to be a slowing of cognitive decline at a dose-dependent manner, and also a dose-dependent slowing in functional decline," said study co-author Dr. Stephen Salloway.
 
The next phase of the study will definitively answer whether aducanumab holds cognitive benefits for Alzheimer’s patients. A total of 2,700 patients are slated to be enrolled in this next phase, which will be an international effort involving North America, Europe, and Asia.
 
 
Additional sources: BBC, Nature News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
FEB 06, 2020
Clinical & Molecular DX
FEB 06, 2020
Concussion detector could pick up concussions in athletes, right from the sidelines
Concussions are brain traumas caused by a blow to the head or a whiplash injury. The risk of concussions are greatly hei ...
MAR 23, 2020
Genetics & Genomics
MAR 23, 2020
Diagnosing Cancer by Looking for Microbial DNA in the Blood
Liquid biopsies aim to diagnose a disease with only a bit of biological fluid, usually blood.
MAR 24, 2020
Genetics & Genomics
MAR 24, 2020
Crumpling Graphene Makes It an Ultra-Sensitive Biosensor
Liquid biopsies often need to make many copies of RNA or DNA before they are detectable. New research aims to change tha ...
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 20, 2020
Clinical & Molecular DX
MAY 20, 2020
QMS Competencies Your Reagent Supplier Should Possess
The ability of a clinical laboratory to provide consistent and reliable results to their customers depends on the consis ...
Loading Comments...